IART – Market expectations are for Uniform ROA compression, but management is confident about organic growth, orthopedics, and their guidance

• Integra LifeSciences Holdings Corporation (IART:USA) currently trades near corporate averages relative to UAFRS-based (Uniform) Earnings, with a 22.7x Uniform P/E. At these levels, markets are pricing in bearish expectations for the firm, but management is confident about their organic revenue growth, orthopedics business, and revenue guidance
  

• Specifically, management is confident about their bone cutting segment growth, that they will achieve 5% organic revenue growth for the year, and that they expect to see improvements in the orthopedics business in Q4 and going forward. In addition, they are confident they are tightening their revenue guidance range because of their
  year-to-date performance and Q4 expectations, and that they can get back to
  mid-single-digit growth for their private labels in the long-term